APEIRON Biologics

www.apeiron-biologics.com

Apeiron Biologics AG is a privately financed Biotech company in Vienna, Austria. The company currently employs around 25 people and has a strong focus on immunological approaches to treat cancer. In 2010, Apeiron out-licensed itslead project (a recombinant enzyme for the treatment of Acute Respiratory Distress Syndrome and other diseases) to GSK in a deal potentially worth €236 million. Subsequently, Apeiron in-licensed several clinical projects (a liposomal formulation of SOD, a fusion protein and a monoclonal antibody against neuroblastoma) to complement its innovative in-house projects

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

SPATIAL BIOLOGY CRO FLAGSHIP BIOSCIENCES ACQUIRES PHARMA SERVICES BUSINESS FROM INTERPACE BIOSCIENCES

Flagship Biosciences, Inc. | September 01, 2022

news image

Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the acquisition of Interpace Pharma Solutions® a division of Interpace Biosciences and provider of cytogenetic, molecular pathology, and genomic profiling solutions. This acquisition follows a growth equity investment in Flagship from Ampersand Capital Partners, BroadOak Capital Partners, and Research Corporation Technologies. The strategic combination of Flagship and IPS creates a full repert...

Read More

MedTech

GINKGO BIOWORKS ANNOUNCES STRATEGIC PURCHASE OF EPIDEMIOLOGICAL DATA INFRASTRUCTURE ASSETS

Ginkgo Bioworks | August 20, 2022

news image

Ginkgo Bioworks the leading horizontal platform for cell programming, announced the purchase of certain epidemiological data infrastructure assets from Baktus, Inc., a Delaware-based public benefit corporation. Under the terms of the deal, Ginkgo will assume ownership of proprietary datasets, modeling and analytic tools, and a software platform with the capabilities to track, model, and forecast epidemics and associated risks and impacts. Ginkgo also expects to integrate several ongoing epidemio...

Read More

Industry Outlook

ENVEDA BIOSCIENCES UNVEILS NEW AI ALGORITHM TO UNLOCK NATURE’S CHEMICAL CODE

Businesswire | June 26, 2023

news image

Enveda Biosciences, a biotechnology company discovering new medicines from natural sources, released the details of one of its foundational AI models, MS2Mol, in a pre-print posted on ChemRxiv. MS2Mol is designed to predict the structure of metabolites, which are the building blocks and breakdown products of the cell. Despite their essential role in all cell processes, it is estimated that less than 1% of all naturally-occurring metabolites are known to science. The ability of MS2Mol to ra...

Read More

AGC BIOLOGICS PARTNERS WITH TAKARA BIO TO MANUFACTURE PLASMID DNA VACCINE AGAINST COVID-19

AGC Biologics | May 22, 2020

news image

AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals, has announced its partnership with Takara Bio. The companies will partner in the fight against COVID-19 by collaborating on a prophylaxis DNA vaccine,...

Read More
news image

Cell and Gene Therapy

SPATIAL BIOLOGY CRO FLAGSHIP BIOSCIENCES ACQUIRES PHARMA SERVICES BUSINESS FROM INTERPACE BIOSCIENCES

Flagship Biosciences, Inc. | September 01, 2022

Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the acquisition of Interpace Pharma Solutions® a division of Interpace Biosciences and provider of cytogenetic, molecular pathology, and genomic profiling solutions. This acquisition follows a growth equity investment in Flagship from Ampersand Capital Partners, BroadOak Capital Partners, and Research Corporation Technologies. The strategic combination of Flagship and IPS creates a full repert...

Read More
news image

MedTech

GINKGO BIOWORKS ANNOUNCES STRATEGIC PURCHASE OF EPIDEMIOLOGICAL DATA INFRASTRUCTURE ASSETS

Ginkgo Bioworks | August 20, 2022

Ginkgo Bioworks the leading horizontal platform for cell programming, announced the purchase of certain epidemiological data infrastructure assets from Baktus, Inc., a Delaware-based public benefit corporation. Under the terms of the deal, Ginkgo will assume ownership of proprietary datasets, modeling and analytic tools, and a software platform with the capabilities to track, model, and forecast epidemics and associated risks and impacts. Ginkgo also expects to integrate several ongoing epidemio...

Read More
news image

Industry Outlook

ENVEDA BIOSCIENCES UNVEILS NEW AI ALGORITHM TO UNLOCK NATURE’S CHEMICAL CODE

Businesswire | June 26, 2023

Enveda Biosciences, a biotechnology company discovering new medicines from natural sources, released the details of one of its foundational AI models, MS2Mol, in a pre-print posted on ChemRxiv. MS2Mol is designed to predict the structure of metabolites, which are the building blocks and breakdown products of the cell. Despite their essential role in all cell processes, it is estimated that less than 1% of all naturally-occurring metabolites are known to science. The ability of MS2Mol to ra...

Read More
news image

AGC BIOLOGICS PARTNERS WITH TAKARA BIO TO MANUFACTURE PLASMID DNA VACCINE AGAINST COVID-19

AGC Biologics | May 22, 2020

AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals, has announced its partnership with Takara Bio. The companies will partner in the fight against COVID-19 by collaborating on a prophylaxis DNA vaccine,...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us